Results 201 to 210 of about 55,011 (304)

Glucagon-Like Peptide-1 Receptor Agonists and Hepatocellular Carcinoma Prevention: A Meta-Analysis and Clinical Decision Framework. [PDF]

Cancer Med
Dalbeni A, Vicardi M, Natola LA, Cattazzo F, Auriemma A, Lombardi R, Cinque F, Dalle Carbonare L, Mantovani A, Sacerdoti D.   +9 more
europepmc   +1 more source

Semaglutide and cardiovascular risk in type 1 diabetes: A predictive modelling analysis in a double‐blind, randomised, placebo‐controlled cross‐over trial

Diabetes, Obesity and Metabolism, EarlyView.
Luxcia Kugathasan, Michael A. Tsoukas, Massimo Nardone, Vikas S. Sridhar, Marcel H. A. Muskiet, David Z. I. Cherney, Ahmad Haidar, Melissa‐Rosina Pasqua   +7 more
wiley   +1 more source

Efficacy of probiotics (Bifidobacterium bifidum G9‐1) in patients with type 2 diabetes mellitus and chronic kidney disease complicated by constipation: An exploratory, multicenter, open‐label, single‐arm study (BIRDIE study)

Journal of Diabetes Investigation, EarlyView.
Bifidobacterium bifidum G9‐1 improved stool form, defecation frequency, and Quality of Life in patients with type 2 diabetes mellitus and chronic kidney disease complicated by constipation. ABSTRACT Introduction Although constipation is a major complication of type 2 diabetes mellitus and chronic kidney disease, evidence for its treatment in these ...
Fuki Ikeda, Junko Sato, Hidenori Yoshii, Masahiro Sugawara, Hiroaki Satoh, Yukiko Sugawara, Hirotsugu Uzawa, Daisuke Sugimoto, Reina Muto, Yuya Nishida, Hirotaka Watada   +10 more
wiley   +1 more source

Glucagon‐like peptide 1 receptor agonist for peripheral artery disease: Is it time to proceed? [PDF]

Dario Giugliano, Paola Caruso, Maria Ida Maiorino, Giuseppe Bellastella, Katherine Esposito   +4 more
openalex   +1 more source

Retrospective comparison of the clinical effects of oral semaglutide and SGLT2 inhibitors treatment in patients with type 2 diabetes

Journal of Diabetes Investigation, EarlyView.
This retrospective study compared oral semaglutide and SGLT2 inhibitors in patients with type 2 diabetes over 6 months. Both treatments significantly reduced HbA1c, body weight, and fat mass. Although the reduction in fat mass was comparable, changes in skeletal muscle mass tended to be less favorable with SGLT2 inhibitors than with oral semaglutide ...
Yasuhiro Omori, Ryota Usui, Yuji Yamazaki, Hitoshi Kuwata, Yoshiyuki Hamamoto, Yuichiro Yamada, Yutaka Seino   +6 more
wiley   +1 more source

The Role of Glucagon-like Peptide-1 Receptor Agonists in Alzheimer's and Parkinson's Disease: A Literature Review of Clinical Trials. [PDF]

Life (Basel)
Pilśniak J, Węgrzynek-Gallina J, Bednarczyk B, Buczek A, Pilśniak A, Chmiela T, Jarosińska A, Siuda J, Holecki M.   +8 more
europepmc   +1 more source

Endogenous GIP signaling is indispensable for DPP‐4 inhibitor‐mediated metabolic control in mice

Journal of Diabetes Investigation, EarlyView.
This study reveals that the metabolic benefits of DPP‐4 inhibitors, including improved glucose tolerance and reduced body weight, are completely abolished in GIP receptor‐deficient mice. These findings establish that endogenous GIP signaling, rather than GLP‐1, is the indispensable key player for the efficacy of this drug class.
Saki Kubota‐Okamoto, Sodai Kubota, Hiromi Tsuchida, Yanyan Liu, Seiya Banno, Toshinori Imaizumi, Taro Fujisawa, Yoshihiro Takahashi, Takehiro Kato, Yukio Horikawa, Katsumi Iizuka, Takaaki Murakami, Yuuka Fujiwara, Hitoshi Kuwata, Yuji Yamazaki, Yutaka Seino, Shin Tsunekawa, Daisuke Yabe   +17 more
wiley   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists: A New Era in Cardiometabolic and Cardiovascular Care

Masih Tajdini
openalex   +1 more source

Research progress on oral glucagon-like peptide-1 receptor agonists in the treatment of diabetes mellitus type 2. [PDF]

Front Mol Biosci
Shao Q, Xiong J, Wu J, Mao J, Hu Q.
europepmc   +1 more source

Safety of anagliptin/metformin combination tablets evaluated by non‐inferiority between pre‐ and post‐serum lactic acid levels in Japanese patients with type 2 diabetes and moderate renal impairment (AMELIO STUDY)

Journal of Diabetes Investigation, EarlyView.
To investigate the safety of anagliptin/metformin combination tablets in Japanese patients of type 2 diabetes with moderate renal impairment. This study demonstrates that the fixed‐dose combination of anagliptin and metformin can be used safely in patients with type 2 diabetes complicated by moderate renal dysfunction.
Hiroshi Kajio, Ryotaro Bouchi, Mitsuhisa Komatsu, Masanori Yamazaki, Daisuke Takarabe, Masahide Okamoto, Takahisa Tanaka, Toru Kitazawa, Hisayuki Katsuyama, Yasumichi Mori, Mitsuhiko Noda   +10 more
wiley   +1 more source